Alumis Inc. announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock at $17.00 per share, expected to raise approximately $300.0 million. The offering, expected to close on January 9, 2026, with an option for underwriters to purchase an additional 2,647,500 shares. The joint book-running managers for the offering are Morgan Stanley, Leerink Partners, Cantor, and Wells Fargo Securities. The public offering is made pursuant to a shelf registration statement on Form S-3. Alumis is a biopharmaceutical company developing targeted therapies for immune-mediated diseases, including envudeucitinib for plaque psoriasis and systemic lupus erythematosus.

Read more at GlobeNewswire: Alumis Announces Pricing of Upsized Public Offering of